TruScreen Group Limited

ASX:TRU ISIN:NZTRUE0001S7

TruScreen Group LimitedTruScreen Group Limited (NZE:TRU) (ASX:TRU) is a New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening devices, that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.

TruScreen's cervical screening technology effectively resolves many of the ongoing issues with cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.

The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China.

TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, and Saudi Arabia, where no large-scale cervical cancer screening programs and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.

 
   

News

TruScreen Group Limited (NZE:TRU) (ASX:TRU) - Key Markets Update

🕔11/13/2024 7:48:10 AM 1158

TruScreen Group Limited (NZE:TRU) (ASX:TRU) is pleased to provide an update of its key markets and target markets.

Read Full Article
###

202 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 58) (Last 30 Days: 201) (Since Published: 202) 

Company Data

    Headquarters
  • Suite 3.03, 18-20 Orion Rd
    Lane Cove NSW 2066
    Australia
  • Telephone
  • +61 (0) 2 8999 3820 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.truscreen.com
  • E:
  • info@truscreen.com

More News Results

  • 2024/11/12: TruScreen Key Markets Update*
  • 2024/11/11: Germany's Springer Nature Journal Publication on Truscreen*
  • 2024/10/29: Ranked in Top 6 Global Women's Health Startups 2024 Report*
  • 2024/10/03: TruScreen Featured in UNITAID Technology Landscape Report*
  • 2024/09/23: Dr Dexter Cheung Appointed Chair of Technology Committee*
  • 2024/09/03: Results of Meeting*
  • 2024/09/03: Annual Shareholder Meeting Presentation*
  • 2024/08/16: Notice of Annual General Meeting/Proxy Form*
  • 2024/08/05: Truscreen Outperforms Pap Smear in Saudi Arabia Study*
  • 2024/08/05: Shareholder Meeting and Director Nomination Dates*
*refer to company website

Social Media